China NMPA granted Breakthrough Designation (BTD) for IBI351 for the treatment of previously treated CRC patients with KRASG12C mutation

IBI351 is the first KRASG12C inhibitor that received NMPA BTD for advanced CRC

This designation was supported by data from a pooled analysis of a Phase 1/2 trial and Phase 1 trial, which collectively included 54 patients with CRC

The results of this study will be presented at ASCO 2023